LXEO
Lexeo Therapeutics, Inc.
Price Chart
Latest Quote
$4.89
-0.03 (-0.61%)
Current Price
| Previous Close | $4.92 |
| Open | $4.98 |
| Day High | $5.09 |
| Day Low | $4.85 |
| Volume | 790,512 |
Stock Information
| Shares Outstanding | 78.52M |
| Total Debt | $7.37M |
| Cash Equivalents | $193.04M |
| Net Income | $-87.50M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $383.97M |
| EPS (TTM) | $-1.12 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $197.51M |
| Income | $-87.50M |
| Book/sh | $3.12 |
| Cash/sh | $2.46 |
| Employees | 59 |
Financial Ratios
| Quick Ratio | 13.61 |
| Current Ratio | 14.16 |
| Debt/Eq | 3.18 |
Returns & Margins
| ROA | -32.50% |
| ROE | -54.75% |
Ownership
| Insider Ownership | 0.60% |
| Institutional Ownership | 115.47% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.92 |
| P/B | 1.56 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $20.90 |
Technical Indicators
| SMA20 | $4.68 |
| SMA50 | $5.35 |
| SMA200 | $7.15 |
| RSI | 59.07 |
| ATR | 0.3815 |
| Shares Float | 47.51M |
| Short Float | 20.62% |
| Short Ratio | 19.23 |
| Volatility | 1.39 |
| Rel Volume | 0.98 |
Performance History
| Week | +2.95% |
| Month | -4.31% |
| Quarter | -11.09% |
| 6 Months | -52.75% |
| YTD | -49.12% |
| Year | +23.48% |
| 10 Years | -51.34% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $4.89 | 822,600 |
| 2026-06-23 | $4.92 | 762,600 |
| 2026-06-22 | $5.04 | 1,529,900 |
| 2026-06-18 | $4.93 | 1,481,300 |
| 2026-06-17 | $4.98 | 1,421,100 |
| 2026-06-16 | $4.75 | 724,400 |
| 2026-06-15 | $4.65 | 2,464,200 |
| 2026-06-12 | $4.37 | 624,800 |
| 2026-06-11 | $4.20 | 591,100 |
| 2026-06-10 | $4.13 | 487,700 |
| 2026-06-09 | $4.24 | 437,800 |
| 2026-06-08 | $4.21 | 501,900 |
| 2026-06-05 | $4.37 | 465,600 |
| 2026-06-04 | $4.78 | 534,000 |
| 2026-06-03 | $4.50 | 628,900 |
| 2026-06-02 | $4.51 | 812,500 |
| 2026-06-01 | $4.81 | 799,700 |
| 2026-05-29 | $5.14 | 666,800 |
| 2026-05-28 | $5.08 | 504,400 |
| 2026-05-27 | $5.09 | 589,300 |
| 2026-05-26 | $5.14 | 601,600 |
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
đ° Latest News
Will Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely?
Simply Wall St. âĸ 2026-04-01T10:48:27Z
Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference
MarketBeat âĸ 2026-02-28T21:06:58Z
Lexeo Therapeutics Details FDA Path for LX2006, Highlights LVMI Gains at Guggenheim Biotech Summit
MarketBeat âĸ 2026-02-14T08:11:33Z
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)âs PKP2 Program
Insider Monkey âĸ 2026-02-02T14:54:25Z
Insmedâs âginormousâ lung drug sales; J&Jâs US pricing deal
BioPharma Dive âĸ 2026-01-09T11:28:00Z
Wall Street Rallies Behind Lexeo Therapeutics (LXEO)âs Gene Therapy Pipeline
Insider Monkey âĸ 2025-12-27T12:28:38Z
Raymond James Sees an Attractive Setup in These 2 âStrong Buyâ Stocks
TipRanks âĸ 2025-12-26T00:00:06Z
Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheimâs Stock Picks with Huge Upside Potential
Insider Monkey âĸ 2025-11-03T10:32:25Z
Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise
Insider Monkey âĸ 2025-10-26T10:05:58Z
Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High?
Zacks âĸ 2025-10-23T13:55:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $654,000 |
| Operating Revenue | $0 | $0 | $0 | $654,000 |
| Expenses | ||||
| Interest Expense | $206,000 | $137,000 | $205,000 | $91,000 |
| Total Expenses | $109,257,000 | $105,766,000 | $68,513,000 | $61,163,000 |
| Other Income Expense | $3,372,000 | $-9,000 | $-543,000 | $-2,000 |
| Other Non Operating Income Expenses | $-18,000 | $-9,000 | $-13,000 | $-2,000 |
| Net Non Operating Interest Income Expense | $5,924,000 | $7,442,000 | $2,662,000 | $1,234,000 |
| Interest Expense Non Operating | $206,000 | $137,000 | $205,000 | $91,000 |
| Operating Expense | $109,257,000 | $105,766,000 | $68,513,000 | $61,163,000 |
| General And Administrative Expense | $45,460,000 | $31,675,000 | $15,383,000 | $12,001,000 |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-99,961,000 | $-98,333,000 | $-66,394,000 | $-59,277,000 |
| Net Interest Income | $5,924,000 | $7,442,000 | $2,662,000 | $1,234,000 |
| Interest Income | $6,130,000 | $7,579,000 | $2,867,000 | $1,325,000 |
| Normalized Income | $-103,351,000 | $-98,333,000 | $-65,864,000 | $-59,277,000 |
| Net Income From Continuing And Discontinued Operation | $-99,961,000 | $-98,333,000 | $-66,394,000 | $-59,277,000 |
| Total Operating Income As Reported | $-109,257,000 | $-105,766,000 | $-68,513,000 | $-60,509,000 |
| Net Income Common Stockholders | $-99,961,000 | $-98,333,000 | $-66,394,000 | $-59,277,000 |
| Net Income | $-99,961,000 | $-98,333,000 | $-66,394,000 | $-59,277,000 |
| Net Income Including Noncontrolling Interests | $-99,961,000 | $-98,333,000 | $-66,394,000 | $-59,277,000 |
| Net Income Continuous Operations | $-99,961,000 | $-98,333,000 | $-66,394,000 | $-59,277,000 |
| Pretax Income | $-99,961,000 | $-98,333,000 | $-66,394,000 | $-59,277,000 |
| Interest Income Non Operating | $6,130,000 | $7,579,000 | $2,867,000 | $1,325,000 |
| Operating Income | $-109,257,000 | $-105,766,000 | $-68,513,000 | $-60,509,000 |
| Special Income Charges | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-1.86 | $-3.09 | $-12.40 | $-2.36 |
| Basic EPS | $-1.86 | $-3.09 | $-12.40 | $-2.36 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-101,066,000 | $-96,194,000 | $-63,816,000 | $-58,041,000 |
| Total Unusual Items | $3,390,000 | - | $-530,000 | - |
| Total Unusual Items Excluding Goodwill | $3,390,000 | - | $-530,000 | - |
| Reconciled Depreciation | $2,079,000 | $2,002,000 | $1,843,000 | $1,145,000 |
| EBITDA (Bullshit earnings) | $-97,676,000 | $-96,194,000 | $-64,346,000 | $-58,041,000 |
| EBIT | $-99,755,000 | $-98,196,000 | $-66,189,000 | $-59,186,000 |
| Diluted Average Shares | $53,645,323 | $31,787,491 | $5,354,368 | $25,169,328 |
| Basic Average Shares | $53,645,323 | $31,787,491 | $5,354,368 | $25,169,328 |
| Diluted NI Availto Com Stockholders | $-99,961,000 | $-98,333,000 | $-66,394,000 | $-59,277,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $3,390,000 | - | $-530,000 | - |
| Research And Development | $63,797,000 | $74,091,000 | $53,130,000 | $49,162,000 |
| Selling General And Administration | $45,460,000 | $31,675,000 | $15,383,000 | $12,001,000 |
| Other Gand A | $45,460,000 | $31,675,000 | $15,383,000 | $12,001,000 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $246,669,000 | $116,842,000 | $113,535,000 | $-112,954,000 |
| Total Assets | $268,688,000 | $146,942,000 | $139,807,000 | $97,076,000 |
| Total Non Current Assets | $80,296,000 | $20,821,000 | $15,513,000 | $17,028,000 |
| Other Non Current Assets | $3,248,000 | $3,252,000 | $3,252,000 | $3,253,000 |
| Investmentin Financial Assets | $64,801,000 | $7,012,000 | $0 | - |
| Current Assets | $188,392,000 | $126,121,000 | $124,294,000 | $80,048,000 |
| Other Current Assets | $6,625,000 | $4,603,000 | $2,828,000 | $371,000 |
| Cash Cash Equivalents And Short Term Investments | $181,767,000 | $121,518,000 | $121,466,000 | $77,335,000 |
| Cash And Cash Equivalents | $63,000,000 | $35,014,000 | $121,466,000 | $77,335,000 |
| Prepaid Assets | - | - | $2,825,000 | $2,342,000 |
| Non Current Prepaid Assets | - | - | - | $0 |
| Debt | ||||
| Total Debt | $7,886,000 | $9,924,000 | $11,638,000 | $13,482,000 |
| Long Term Debt And Capital Lease Obligation | $5,211,000 | $7,254,000 | $9,033,000 | $10,648,000 |
| Current Debt And Capital Lease Obligation | $2,675,000 | $2,670,000 | $2,605,000 | $2,834,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $22,019,000 | $30,100,000 | $26,272,000 | $210,030,000 |
| Total Non Current Liabilities Net Minority Interest | $5,211,000 | $7,254,000 | $9,033,000 | $195,681,000 |
| Current Liabilities | $16,808,000 | $22,846,000 | $17,239,000 | $14,349,000 |
| Other Current Liabilities | $73,000 | $545,000 | $554,000 | $240,000 |
| Payables And Accrued Expenses | $9,994,000 | $15,519,000 | $11,270,000 | $9,364,000 |
| Payables | $4,856,000 | $6,417,000 | $3,794,000 | $3,184,000 |
| Accounts Payable | $4,856,000 | $6,417,000 | $3,794,000 | $2,678,000 |
| Total Tax Payable | - | - | $157,000 | $506,000 |
| Current Deferred Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $246,669,000 | $116,842,000 | $113,535,000 | $-112,954,000 |
| Total Equity Gross Minority Interest | $246,669,000 | $116,842,000 | $113,535,000 | $-112,954,000 |
| Stockholders Equity | $246,669,000 | $116,842,000 | $113,535,000 | $-112,954,000 |
| Gains Losses Not Affecting Retained Earnings | $188,000 | $-103,000 | $0 | - |
| Other Equity Adjustments | $188,000 | $-103,000 | - | - |
| Retained Earnings | $-380,134,000 | $-280,173,000 | $-181,840,000 | $-115,446,000 |
| Long Term Equity Investment | $3,390,000 | $0 | - | - |
| Preferred Securities Outside Stock Equity | - | - | $0 | $185,033,000 |
| Other | ||||
| Treasury Shares Number | $3,827 | $3,827 | $22,107 | - |
| Ordinary Shares Number | $72,997,939 | $33,075,382 | $26,646,378 | $25,169,328 |
| Share Issued | $73,001,766 | $33,079,209 | $26,668,485 | $25,169,328 |
| Tangible Book Value | $246,669,000 | $116,842,000 | $113,535,000 | $-112,954,000 |
| Invested Capital | $246,669,000 | $116,842,000 | $113,535,000 | $-112,954,000 |
| Working Capital | $171,584,000 | $103,275,000 | $107,055,000 | $65,699,000 |
| Capital Lease Obligations | $7,886,000 | $9,924,000 | $11,638,000 | $13,482,000 |
| Total Capitalization | $246,669,000 | $116,842,000 | $113,535,000 | $-112,954,000 |
| Treasury Stock | $17,000 | $17,000 | $0 | - |
| Additional Paid In Capital | $626,625,000 | $397,132,000 | $295,372,000 | $2,492,000 |
| Capital Stock | $7,000 | $3,000 | $3,000 | $0 |
| Common Stock | $7,000 | $3,000 | $3,000 | $0 |
| Long Term Capital Lease Obligation | $5,211,000 | $7,254,000 | $9,033,000 | $10,648,000 |
| Current Capital Lease Obligation | $2,675,000 | $2,670,000 | $2,605,000 | $2,834,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,066,000 | $4,112,000 | $2,810,000 | $1,911,000 |
| Current Accrued Expenses | $5,138,000 | $9,102,000 | $7,476,000 | $6,180,000 |
| Investments And Advances | $68,191,000 | $7,012,000 | $0 | - |
| Available For Sale Securities | $64,801,000 | $7,012,000 | - | - |
| Net PPE | $8,857,000 | $10,557,000 | $12,261,000 | $13,775,000 |
| Accumulated Depreciation | $-741,000 | $-474,000 | $-381,000 | $-133,000 |
| Gross PPE | $9,598,000 | $11,031,000 | $12,642,000 | $13,908,000 |
| Leases | $272,000 | $272,000 | $247,000 | $232,000 |
| Other Properties | $8,940,000 | $10,373,000 | $11,719,000 | $13,056,000 |
| Machinery Furniture Equipment | $386,000 | $386,000 | $676,000 | $620,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $118,767,000 | $86,504,000 | $0 | - |
| Preferred Stock | - | $0 | $0 | - |
| Current Deferred Revenue | - | - | - | $0 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-98,958,000 | $-81,632,000 | $-59,661,000 | $-55,461,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-98,561,000 | $-81,151,000 | $-59,496,000 | $-54,560,000 |
| Cash Flow From Continuing Operating Activities | $-98,561,000 | $-81,151,000 | $-59,496,000 | $-54,560,000 |
| Operating Gains Losses | $-3,407,000 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-397,000 | $-481,000 | $-165,000 | $-901,000 |
| Investing Cash Flow | $-90,252,000 | $-94,077,000 | $-165,000 | $-901,000 |
| Cash Flow From Continuing Investing Activities | $-90,252,000 | $-94,077,000 | $-165,000 | $-901,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-17,000 | $0 | - |
| Issuance Of Capital Stock | $234,019,000 | $94,999,000 | $100,251,000 | $20,000 |
| Financing Cash Flow | $216,795,000 | $88,776,000 | $103,791,000 | $189,000 |
| Cash Flow From Continuing Financing Activities | $216,795,000 | $88,776,000 | $103,791,000 | $189,000 |
| Net Other Financing Charges | $-16,750,000 | $-6,287,000 | $-86,000 | - |
| Net Common Stock Issuance | $234,019,000 | $94,982,000 | $100,251,000 | $0 |
| Common Stock Issuance | $234,019,000 | $94,999,000 | $100,251,000 | $0 |
| Net Preferred Stock Issuance | - | - | $0 | $20,000 |
| Preferred Stock Issuance | - | - | $0 | $20,000 |
| Other | ||||
| Repayment Of Debt | $-533,000 | $-410,000 | $-425,000 | $-163,000 |
| Interest Paid Supplemental Data | $104,000 | $127,000 | $176,000 | $77,000 |
| End Cash Position | $66,248,000 | $38,266,000 | $124,718,000 | $80,588,000 |
| Beginning Cash Position | $38,266,000 | $124,718,000 | $80,588,000 | $135,860,000 |
| Changes In Cash | $27,982,000 | $-86,452,000 | $44,130,000 | $-55,272,000 |
| Proceeds From Stock Option Exercised | $59,000 | $491,000 | $51,000 | $332,000 |
| Common Stock Payments | $0 | $-17,000 | $0 | - |
| Net Issuance Payments Of Debt | $-533,000 | $-410,000 | $3,575,000 | $-163,000 |
| Net Long Term Debt Issuance | $-533,000 | $-410,000 | $3,575,000 | $-163,000 |
| Long Term Debt Payments | $-533,000 | $-410,000 | $-425,000 | $-163,000 |
| Net Investment Purchase And Sale | $-89,855,000 | $-93,596,000 | $0 | - |
| Sale Of Investment | $105,527,000 | $0 | - | - |
| Purchase Of Investment | $-195,382,000 | $-93,596,000 | $0 | - |
| Net PPE Purchase And Sale | $-397,000 | $-481,000 | $-115,000 | $-672,000 |
| Purchase Of PPE | $-397,000 | $-481,000 | $-115,000 | $-672,000 |
| Change In Working Capital | $-9,515,000 | $2,729,000 | $1,482,000 | $1,791,000 |
| Change In Other Current Liabilities | $-1,505,000 | $-1,326,000 | $-1,419,000 | $-304,000 |
| Change In Payables And Accrued Expense | $-6,006,000 | $5,745,000 | $1,911,000 | $4,028,000 |
| Change In Accrued Expense | $-4,445,000 | $3,367,000 | $2,091,000 | $4,476,000 |
| Change In Payable | $-1,561,000 | $2,378,000 | $-180,000 | $-448,000 |
| Change In Account Payable | $-1,561,000 | $2,378,000 | $-180,000 | $-426,000 |
| Change In Prepaid Assets | $-2,004,000 | $-1,690,000 | $990,000 | $-1,887,000 |
| Stock Based Compensation | $12,132,000 | $12,474,000 | $3,043,000 | $1,781,000 |
| Amortization Of Securities | $111,000 | $-23,000 | $0 | - |
| Depreciation Amortization Depletion | $2,079,000 | $2,002,000 | $1,843,000 | $1,145,000 |
| Depreciation And Amortization | $2,079,000 | $2,002,000 | $1,843,000 | $1,145,000 |
| Depreciation | $2,079,000 | $2,002,000 | $1,843,000 | $1,145,000 |
| Gain Loss On Investment Securities | $-3,407,000 | - | - | - |
| Net Income From Continuing Operations | $-99,961,000 | $-98,333,000 | $-66,394,000 | $-59,277,000 |
| Issuance Of Debt | - | $0 | $4,000,000 | $0 |
| Long Term Debt Issuance | - | $0 | $4,000,000 | $0 |
| Net Intangibles Purchase And Sale | - | $0 | $-50,000 | $-229,000 |
| Purchase Of Intangibles | - | $0 | $-50,000 | $-229,000 |
| Income Tax Paid Supplemental Data | - | - | $0 | $0 |
| Change In Tax Payable | - | - | $-349,000 | $-22,000 |
| Change In Income Tax Payable | - | - | $-349,000 | $-22,000 |
| Other Non Cash Items | - | - | $530,000 | - |
| Change In Other Working Capital | - | - | - | $-46,000 |
Fetched: 2026-06-24